Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: Central plus peripheral nervous system mechanisms

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 203-213

  Lechin, Fuad ^a   Van Der Dijs, Bertha ^a   Pardey Maldonado, Betty ^a   Rivera, Jairo E ^a   Lechin, Marcel E ^b   Baez, Scarlet ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Amantadine; Blood catecholamines; Blood serotonin; Glucagon; Insulin; Sympathetic nervous system; Type 2 diabetes

Indexed keywords

ADRENALIN; AMANTADINE; DOPAMINE; GLUCAGON; GLUCOSE; INSULIN; NORADRENALIN; PLACEBO; SEROTONIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL NERVOUS SYSTEM; SEROTONIN BLOOD LEVEL;

EID: 77952426483     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s7606     Document Type: Article

References (52)

1. Göke B. Islet cell function: alpha and beta cells - partners towards normoglycaemia. Int J Clin Pract Suppl. 2008;(159):2-7.
2. Fanelli CG, Porcellati F, Rossetti P, Bolli GB. Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis. 2006;16(Suppl 1):528-534.
3. Cryer PE. Glucagon and hyperglycaemia in diabetes. Clin Sci (Lond). 2008;114(9):589-590.
4. Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus - "Flatbush diabetes" Pediatr Endocrinol Metab. 2002;15(Suppl 1):493-501.
5. Gelling RW, Vuguin PM, Du XQ, et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab. 2009;297(3):E695-E707.
6. Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979;64(1):62-71.
7. Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology (Bethesda). 2009;24:159-170.
8. Lechin F, van der Dijs B, Benaim M. Stress versus depression. Prog Neuropsychopharmacol Biol Psychiat. 1996;20(6):899-950.
9. Lechin F, Coll-Garcia E, van der Dijs B, Bentolila A, Peña F, Rivas C. Effects of captivity on glucose tolerance in dogs. Experientia. 1979;35(7):876-877.
10. Lechin F, van der Dijs B, Pardey-Maldonado B, Baez S, Lechin ME. Effect of tianeptine on glucose tolerance with insulin secretion in human: Potential anti-diabetic effect of the drug. Open Neuroendocrinol J. 2009;2:10-19.
11. Lechin F, van der Dijs B, Lechin A, et al. Doxepin therapy for post-prandial symptomatic hypoglycemic patients neurochemical, hormonal and metabolic disturbances. Clin Sci. 1991;80(4):373-384.
12. Lechin F, van der Dijs B. Haloperidol and insulin release. Diabetologia. 1981;20(1):78.
13. Lechin F, Coll-Garcia E, van der Dijs B, Bentolila A, Peña F, Rivas C. The effects of dopaminergic blocking agents on the glucose tolerance test in six humans and six dogs. Experientia. 1979;35(7):886-887.
14. Christensen NJ, Hilsted J, Egger M, Teuscher A, Frier BM, Hepburn DA. Plasma noradrenaline, human insulin, and hypoglycaemia. Lancet. 1989;334(8674):1268-1269.
15. Lechin F, van der Dijs B, Lechin M, et al. Effects of an oral glucose load on plasma neurotransmitters in humans: involvement of REM sleep? Neuropsychobiology. 1992;26(1-2):4-11.
16. Abdelmelek H, Fechtali T, Filali-Zegzouti Y, et al. Responsiveness of plasma catecholamines to intracerebroventricular injection of glucagon in Muscovy ducklings. J Neural Transm. 2001;108(7):793-801.
17. Fisher SJ, Brüning JC, Lannon S, Kahn CR. Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes. 2005;54(5):1447-1451.
18. Dampney RA, Goodchild AK, Robertson LG, Montgomery W. Role of ventrolateral medulla in vasomotor regulation: a correlative anatomical and physiological study. Brain Res. 1982;249(2):223-235.
19. Byrum CE, Guyenet PG. Afferent and efferent connections of the A5 noradrenergic cell group in the rat. J Comp Neurol. 1987;261(4): 529-542.
20. Loewy AD, Franklin MF, Haxhiu MA. CNS monoamine cell groups projecting to pancreatic vagal motor neurons: a transneuronal labeling study using pseudorabies virus. Brain Res. 1994;638(1-2): 248-260.
21. Loewy AD, Marson L, Parkinson D, Perry MA, Sawyer WB. Descending noradrenergic pathways involved in the A5 depressor response. Brain Res. 1986;386(1-2):313-324.
22. Loewy AD, Haxhiu MA. CNS cell groups projecting to pancreatic parasympathetic preganglionic neurons. Brain Res. 1993;620(2): 323-330.
23. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595-638.
24. Lechin F, van der Dijs B. Central nervous system circuitries underlying two types of peripheral autonomic nervous system disorders. Open Neurosci J. 2008;2:41-50.
25. Maiorov DN, Wilton ER, Badoer E, Petrie D, Head GA, Malpas SC. Sympathetic response to stimulation of the pontine A5 region in conscious rabbits. Brain Res. 1999;815(2):227-236.
26. Ross CA, Ruggiero DA, Park DH, et al. Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin. J Neurosci. 1984;4(2):474-494.
27. Morrison SF, Callaway J, Milner TA, Reis DJ. Rostral ventrolateral medulla: a source of the glutamatergic innervation of the sympathetic intermediolateral nucleus. Brain Res. 1991;562(1):126-135.
28. Zhou W, Fu LW, Tjen-A-Looi SC, Guo ZL, Longhurst JC. Role of glutamate in a visceral sympathoexcitatory reflex in rostral ventrolateral medulla of cats. Am J Physiol Heart Circ Physiol. 2006;291(3): H1309-H1318.
29. Lechin F, van der Dijs B. Crosstalk between the autonomic nervous system and the central nervous system: Mechanistic and therapeutic considerations for neuronal, immune, vascular, and somatic based diseases. In: Maiese K, editor. Neurovascular Medicine: Pursuing Cellular Longevity for Healthy Aging. New York, NY: Oxford University Press; 2009. p. 101-152.
30. Liu RH, Fung SJ, Reddy VK, Barnes CD. Localization of glutamatergic neurons in the dorsolateral pontine tegmentum projecting to the spinal cord of the cat with a proposed role of glutamate on lumbar motoneuron activity. Neuroscience. 1995;64(1):193-208.
31. Gerendai I, Halász B. Central nervous system structures connected with the endocrine glands. findings obtained with the viral transneuronal tracing technique. Exp Clin Endocrinol Diabetes. 2000;108(6): 389-395.
32. Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem. 1968;14:116-131.
33. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30(3):219-225.
34. Hegedüs L, Christensen NJ, Sestoft L. Abnormal regulation of sympathetic nervous activity and heart rate after oral glucose in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1983;25(3):242-246.
35. Sun MK. Central neural organization and control of sympathetic nervous system in mammals. Prog Neurobiol. 1995;47(3):157-233.
36. Tanaka M, Matsumoto Y, Murakami T, Hisa Y, Ibata Y. The origins of catecholaminergic innervation in the rostral ventromedial medulla oblongata of the rat. Neurosci Lett. 1996;207(1):53-56.
37. Jacoby JH, Bryce GF. The acute pharmacologic effects of serotonin on the release of insulin and glucagon in the intact rat. Arch Int Pharmacodyn Ther. 1978;235(2):254-270.
38. Adeghate E, Ponery AS, Pallot D, Parvez SH, Singh J. Distribution of serotonin and its effect on insulin and glucagon secretion in normal and diabetic pancreatic tissues in rat. Neuro Endocrinol Lett. 1999;20(5):315-322.
39. de Leiva A, Tanenberg RJ, Anderson G, Greenberg B, Senske B, Goetz FC. Serotoninergic activation and inhibition: effects on carbohydrate tolerance and plasma insulin and glucagon. Metabolism. 1978;27(5):511-520.
40. Lechin F, van der Dijs B, Lechin M, et al. Plasma neurotransmitters throughout an oral glucose tolerance test in essential hypertension. Clin Exp Hypertens. 1993;15(1):209-240.
41. Lechin F, van der Dijs B. Central nervous system circuitry involved in the hyperinsulinism syndrome [review]. Neuroendocrinology. 2006;84(4):222-234.
42. Carvalho F, Barros D, Silva J, et al. Hyperglycemia induced by pharmacological activation of central serotonergic pathways depends on the functional integrity of brain CRH system and 5-HT3 receptors. Horm Metab Res. 2005;37(8):482-488.
43. Tobe T. Enterochromaffin cells and carcinoid syndrome. Nippon Rinsho. 1974;32(4):745-750.
44. Reynolds DJ, Leslie RA, Grahame-Smith DG, Harvey JM. Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. Eur J Pharmacol. 1989;174(1):127-130.
45. Lechin F, van der Dijs B. Neuropharmacological therapy of carcinoid syndrome. Neuroendocrinology. 2005;81(3):137-138.
46. Lechin F, van der Dijs B. Intestinal pharmacomanometry and glucose tolerance: evidence for two antagonistic dopaminergic mechanisms in the human. Biol Psychiatry. 1981;16(10):969-971.
47. Lechin F, van der Dijs B. Glucose tolerance, non-nutrient drink and gastrointestinal hormones. Gastroenterology. 1981;80(1):216.
48. Lechin F, van der Dijs B, Orozco B. Cholecystokinin (CCK) and secretin and pancreatic secretion of insulin and glucagon. Dig Dis Sci. 2002;47(11):2422-2423.
49. Lechin F, van der Dijs B. Central nervous system circuitry and peripheral neural sympathetic activity responsible for essential hypertension. Curr Neurovasc Res. 2006;3(4):307-325.
50. Saito M, Saitoh T, Inoue S. Alpha 2-adrenergic modulation of pancreatic glucagon secretion in rats. Physiol Behav. 1992;51(6):1165-1171.
51. Lechin F, van der Dijs B, Hernandez-Adrian G. Dorsal Raphe (DR) vs Median Raphe (MR) serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: Relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4): 565-585.
52. Lechin F, van der Dijs B, Lechin ME. Neurocircuitry and Neuroautonomic Disorders: Reviews and Therapeutic Strategies. Basel, Switzerland: Karger; 2002.